Page 144 - Read Online

Page 678 Murthy et al. Cancer Drug Resist 2019;2:665-79 I http://dx.doi.org/10.20517/cdr.2019.002

peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45.
26. Coleman RL, Brady MF, JHerzog T, Sabbatini P, ArmstrongColeman DK, et al. Bevacizumab and paclitaxel-carboplatin
chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology
Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:779-791.
27. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance Olaparib in patients with newly diagnosed advanced
ovarian Cancer. N Engl J Med 2018;379:2495-505.
28. Spriggs DR, Longo DL. Progress in BRCA-Mutated Ovarian Cancer. N Engl J Med 2018;379:2567-68.
29. Pujade-Lauraine E, Ledermann JA, Selle F,Gebski V, Penson RT, et al. Olaparib tablets as maintenance therapy in patients with
platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-
controlled, phase 3 trial. Lancet Oncol 2017;18:1274-84.
30. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, et al. Combination cediranib and olaparib versus olaparib alone for women
with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014;15:1207-14.
31. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, et al. Olaparib combined with chemotherapy for recurrent platinum-
sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015;16:87-97.
32. Konstantinopoulos PA, Waggoner SE, Vidal GA, Mita MM, Fleming GF, et al. TOPACIO/Keynote-162 (NCT02657889): A phase 1/2
study of niraparib+ pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—
Results from ROC cohort. J Clin Oncol 2018;36:106.
33. Robson M, Im SA, Senkus E, Xu B, Domchek SM, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA
mutation. N Engl J Med 2017;377:523-33.
34. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline
BRCA Mutation. N Engl J Med 2018;379:753-63.
35. Pahuja S, Beumer JH, Appleman LJ, Tawbi HAH, Stoller RG,et al. A phase I study of veliparib (ABT-888) in combination with
weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). J Clin Oncol
2015;33:1015.
36. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, et al. A phase I study of veliparib in combination with metronomic
cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012;18:1726-34.
37. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, et al. A phase II evaluation of the potent, highly selective PARP
inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in
patients who carry a germline BRCA1 or BRCA2 mutation—an NRG oncology/gynecologic oncology group study. Gynecol Oncol
2015;137:386-91.
38. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and
rucaparib. Mol Cancer Ther 2014;13:433-43.
39. Plummer ER, Dua D, Cresti N, Suder A, Drew Y, et al. First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449)
as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker. J
Clin Oncol 2018;36:2505.
40. Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, et al. Phase 1 dose-escalation study of the PARP inhibitor CEP-
9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemoth Pharm 2014;74:257-65.
41. Awada A, Campone M, Varga A, Aftimos P, Frenel JS, et al. An open-label, dose-escalation study to evaluate the safety and
pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with
advanced solid tumors. Anti-cancer Drugs 2016;27:342-8.
42. O’Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, et al. Phase III study of iniparib plus gemcitabine and carboplatin
versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014;32:3840-7.
43. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
Clin Cancer Res 2012;18:1655-62.
44. Gagné JP, Isabelle M, Lo KS, Bourassa S, Hendzel MJ, et al. Proteome-wide identification of poly(ADP-ribose) binding proteins and
poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res 2008;36:6959-76.
45. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci
at sites of oxidative DNA damage. Nucleic Acids Res 2003;31:5526-33.
46. Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, et al. Homologous-recombination-deficient tumours are dependent on Polθ-
mediated repair. Nature 2015;518:258-62.
47. Mateos-Gomez PA, Gong F, Nair N, Miller KM, Lazzerini-Denchi E, et al. Mammalian polymerase θ promotes alternative NHEJ and
suppresses recombination. Nature 2015;518:254-7.
48. Murai J, Huang SN, Das BB, Renaud A, Zhang Y, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res
2012;72:5588-99.
49. Caldecott KW. Protein ADP-ribosylation and the cellular response to DNA strand breaks. DNA repair 2014;19:108-113.
50. Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, et al. Mechanistic Dissection of PARP1 Trapping and the Impact on
In Vivo Tolerability and Efficacy of PARP Inhibitors. Mol Cancer Res 2015;13:1465-77.
51. Hopkins TA, Ainsworth WB, Ellis PA, Donawho CK, DiGiammarino EL, et al. PARP1 Trapping by PARP Inhibitors Drives
Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow. Mol Cancer Res 2019;17:409-419.
52. Grundy GJ, Polo LM, Zeng Z, Rulten SL, Hoch NC, et al. PARP3 is a sensor of nicked nucleosomes and monoribosylates histone